AU2002326271B2 - A combination of quetiapine and zolmitriptan - Google Patents

A combination of quetiapine and zolmitriptan Download PDF

Info

Publication number
AU2002326271B2
AU2002326271B2 AU2002326271A AU2002326271A AU2002326271B2 AU 2002326271 B2 AU2002326271 B2 AU 2002326271B2 AU 2002326271 A AU2002326271 A AU 2002326271A AU 2002326271 A AU2002326271 A AU 2002326271A AU 2002326271 B2 AU2002326271 B2 AU 2002326271B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
quetiapine
zolmitriptan
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002326271A
Other languages
English (en)
Other versions
AU2002326271A1 (en
Inventor
David Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002326271A1 publication Critical patent/AU2002326271A1/en
Application granted granted Critical
Publication of AU2002326271B2 publication Critical patent/AU2002326271B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002326271A 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan Ceased AU2002326271B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102855A SE0102855D0 (sv) 2001-08-27 2001-08-27 Method of treatment
SE0102855-4 2001-08-27
PCT/SE2002/001507 WO2003018009A1 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan

Publications (2)

Publication Number Publication Date
AU2002326271A1 AU2002326271A1 (en) 2003-06-05
AU2002326271B2 true AU2002326271B2 (en) 2007-10-11

Family

ID=20285147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002326271A Ceased AU2002326271B2 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan

Country Status (12)

Country Link
US (2) US20050020571A1 (enExample)
EP (1) EP1423112B1 (enExample)
JP (1) JP2005503391A (enExample)
AT (1) ATE342720T1 (enExample)
AU (1) AU2002326271B2 (enExample)
CA (1) CA2456480A1 (enExample)
DE (1) DE60215525T2 (enExample)
ES (1) ES2274081T3 (enExample)
NZ (1) NZ530930A (enExample)
SE (1) SE0102855D0 (enExample)
WO (1) WO2003018009A1 (enExample)
ZA (1) ZA200401550B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522343A1 (en) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
US20110212980A1 (en) * 2008-10-22 2011-09-01 Novartis Ag Combinations for the treatment of migraine
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
US10457299B2 (en) * 2017-02-22 2019-10-29 Westinghouse Air Brake Technologies Corporation Train stop timer
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
WO1997045124A1 (en) * 1996-05-31 1997-12-04 Zeneca Limited Pharmaceutical compositions
WO2001021179A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quetiapine granules
WO2001039772A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Pharmaceutical formulations containing zolmitriptan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
GB9709815D0 (en) * 1997-05-14 1997-07-09 Merck Sharp & Dohme Therapeutic method
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
WO1997045124A1 (en) * 1996-05-31 1997-12-04 Zeneca Limited Pharmaceutical compositions
WO2001021179A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quetiapine granules
WO2001039772A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Pharmaceutical formulations containing zolmitriptan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. J. Mercer et al. Psychopharmacology. 1998, vol 40, pages 398-404. *
Caley, Charles F et al. Formulary. 1998, vol 33 No 2 pages 105-106, 109-110, 112, 115-116, 119. *

Also Published As

Publication number Publication date
ATE342720T1 (de) 2006-11-15
SE0102855D0 (sv) 2001-08-27
JP2005503391A (ja) 2005-02-03
DE60215525D1 (de) 2006-11-30
CA2456480A1 (en) 2003-03-06
ZA200401550B (en) 2004-11-17
US20080108596A1 (en) 2008-05-08
EP1423112B1 (en) 2006-10-18
EP1423112A1 (en) 2004-06-02
US20050020571A1 (en) 2005-01-27
WO2003018009A1 (en) 2003-03-06
NZ530930A (en) 2006-01-27
DE60215525T2 (de) 2007-06-06
ES2274081T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
JP3638289B2 (ja) ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
JP2011141287A (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US20190328750A1 (en) Treatment of demyelinating diseases
RU2528892C2 (ru) Ветеринарная антипролактиновая композиция для жвачных
US20080108596A1 (en) Combination of Quetiapine and Zolmitriptan
US6054455A (en) Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
JP5049139B2 (ja) 内臓痛を治療するためのオキシコドンの使用
TW202539669A (zh) 雌激素受體降解劑之給藥方案
RU2308268C2 (ru) Производные арил- или гетероарилазолилкарбинолов для лечения недержания мочи
RU2423146C2 (ru) Лекарственное средство для лечения эндометриоза
MXPA05001705A (es) Uso de reboxetina para el tratamiento de sofocos.
US20080194631A1 (en) Medicament For the Treatment of Central Nervous System Disorders
AU2002326271A1 (en) A combination of quetiapine and zolmitriptan
JPH02180828A (ja) 男性不能症の治療用物質
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
Zentgraf et al. How safe is the treatment of impotence with intracavernous autoinjection?
JP2008519810A (ja) 顔面紅潮の治療のためのｓミルタザピン
JP2007517822A (ja) 遺尿症を治療するためのアリール（またはヘテロアリール）アゾリルカルビノールの誘導体
EP1952813A1 (en) Medicament for the treatment of endometriosis
Abdel-Hamid Pharmacologic treatment of rapid ejaculation: levels of evidence-based review
Mannix et al. Women and headache: a treatment approach based on life stages
WO2005016319A2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CZ20031727A3 (cs) Nové terapeutické použití derivátu thienylcyklohexylaminu
HK40127185A (en) Dosage regimens of estrogen receptor degraders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired